Sagimet Biosciences (SGMT) Amortizatization of Intangibles (2022 - 2026)
Sagimet Biosciences' (SGMT) quarterly Amortizatization of Intangibles came in at $140000.0 in Q1 2026, down 73.83% year-on-year from $535000.0 in Q1 2025, and up 146.67% quarter-over-quarter from -$300000.0 in Q4 2025.
Sagimet Biosciences (SGMT) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $140000.0 for Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles fell 73.83% year-over-year to $140000.0 in Q1 2026; TTM through Mar 2026 was -$6000.0, a 100.38% decrease from a year earlier, with the FY2025 full-year figure at $389000.0, down 68.95% from the prior year.
- Amortizatization of Intangibles climbed to $140000.0 in Q1 2026 per SGMT's latest filing, from -$300000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $535000.0 in Q1 2025 and bottomed at -$300000.0 in Q4 2025.
- The 5-year median for Amortizatization of Intangibles is $85500.0 (2022), against an average of $142142.9.
- Across the five-year window, Amortizatization of Intangibles surged 11825.0% in 2024 and tumbled 635.71% in 2025, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $83000.0 in 2022, then plunged by 102.41% to -$2000.0 in 2023, then jumped by 2900.0% to $56000.0 in 2024, then tumbled by 635.71% to -$300000.0 in 2025, then jumped by 146.67% to $140000.0 in 2026.
- Per Business Quant, the three latest SGMT Amortizatization of Intangibles figures stand at $140000.0 (Q1 2026), -$300000.0 (Q4 2025), and -$72000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 3.22 Mn |
| 10 | Sagimet Biosciences | 227.27 Mn | 227.27 Mn | - | 140,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 140,000.00 |
| Mar 31, 2026 | 140,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Sep 30, 2025 | -72,000.00 |
| Sep 30, 2025 | -72,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Mar 31, 2025 | 535,000.00 |
| Mar 31, 2025 | 535,000.00 |
| Dec 31, 2024 | 56,000.00 |
| Dec 31, 2024 | 56,000.00 |
| Sep 30, 2024 | 527,000.00 |
| Sep 30, 2024 | 527,000.00 |
| Jun 30, 2024 | 477,000.00 |
| Jun 30, 2024 | 477,000.00 |
| Mar 31, 2024 | 193,000.00 |
| Mar 31, 2024 | 193,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Dec 31, 2023 | -2,000.00 |